Abstract
The sirtuins (SIRT 1-7) comprise a family of NAD+ dependent protein modifying enzymes with activities in lysine deacetylation, ADP-ribosylation, and/or deacylation. These enzymes are involved in the cell’s stress response systems and in regulating gene expression, DNA damage repair, metabolism and survival. Sirtuins play complex roles in both promoting and/or suppressing tumorigenesis. This review presents recent research progress concerning sirtuins and cancer. On one hand, functional loss of sirtuin genes, particularly SIRT1, involved in maintaining genome integrity and DNA repair will promote tumorigenesis due to genomic instability upon their loss. On the other hand, cancer cells tend to require sirtuins for these same processes to allow them to survive, proliferate, repair the otherwise catastrophic genomic events and evolve. The bifurcated roles of SIRT1, and perhaps several other sirtuins, in cancer may be in part a result of the nature of the genes that are involved in the cell’s genome maintenance systems. The in-depth understanding of sirtuin functions may have significant implication in designing precise modulation of selective sirtuin members to aid cancer prevention or treatment under defined conditions.
INTRODUCTION
Sirtuins are mammalian homologs of yeast silent information regulator 2 (Sir2) encoding a histone deacetylase.1, 2 The seven mammalian members of sirtuins (termed SIRT1-7) share a conserved catalytic core domain (Fig. 1). Despite this homology, sirtuins have divergent enzymatic activities with SIRT1-3 and SIRT7 primarily as lysine deacetylases, SIRT4 primarily as ADP-ribosyltransferase, SIRT5 as deacetylase and deacylase, and SIRT6 as ADP-ribosyltransferase and deacetylase.1-5 In addition, primary localization of these proteins in the cell varies significantly, reflecting functional distinction of sirtuin members (See Fig. 1).
Fig. 1.
Comparison of mammalian sirtuins.
The amino acid length of each mature main form of sirtuins is indicated at the end of each protein, with the conserved catalytic domain illustrated in grey. Principal enzymatic activities and primary cellular localization are shown.
Growing interest in sirtuins largely stems from previous studies of yeast Sir2 showing that in lower organisms, increased Sir2 gene dosage is sufficient to extend lifespan,6-8 and that Sir2 is at a nexus between caloric restriction (CR), resveratrol or other CR mimetics and longevity. 9,10 More recently, these initial observations have been scrutinized and refined to show a lack of an effect of Sir2 in extending lifespan in lower species as well as in mammals.11-13 Further adding to the complex nature of the role of sirtuins in extending lifespan, Kanfi et al described that transgenic SIRT6 male mice live approximately 10-15% longer than their wild-type littermates.14 The conflicting literature on the roles of Sir2 in longevity contributes in part to the confusion of functions of mammalian sirtuins, but may also foretell the complexity of these genes in mammalian cells.
Research in the past decade has revealed the perplexed and often controversial roles of sirtuins in promoting versus suppressing cancer. Cancer cells alter normal cellular machineries to promote unabated cell proliferation and maximize their lifespan, but as a consequence of their malignant growth, they cut short the lifespan of the host organism. Hanahan and Weinberg have elegantly outlined the fundamental mechanisms of cancer promotion as consisting of sustaining proliferative signaling, enabling replicative immortality, activating invasion and metastasis and inducing angiogenesis; meanwhile, as normal cells possess innate mechanisms to antagonize cancer promoting signals, the transformed cells must also overcome tumor suppression mechanisms, namely, by evading growth suppressor signals and resisting cell death.15 Crucially underlying these hallmarks of cancer is the genetic instability of cancer cells.15 Although cancer biologists tend to classify genes into either tumor promoting or tumor suppressing, only a limited number of genes unambiguously fall into one of these categories, for examples, MYC as an oncogene and retinoblastoma gene RB as a tumor suppressor gene.16 Other genes including sirtuins are less apparent, and the tumor promoting or inhibiting properties of the genes may depend on the stages of cancer development and contextual variables such as tissue of origin, the microenvironment and the exact experimental conditions.15 However, rapid progress has been made most recently in the research on mammalian sirtuins and cancer, which may improve our understanding of these elusive genes and will be highlighted in this review.
SIRT1
Biochemical Overview
SIRT1 shares the greatest homology with yeast Sir2 that was initially characterized as an NAD+ dependent histone deacetylase2 (so called Class III HDAC that is structurally and biochemically distinct from Class I, II and IV HDACs). SIRT1 deacetylates histone H4 lysine 16 (H4K16) as well as histone H3 lysine 9 and 14 (H3K9 and H3K14, respectively).1 Additionally, SIRT1 deacetylates histone H1 lysine 26 (H1K26) and is involved in the deposition of histone variants.17 These modifications of histone tails are closely related to gene silencing and heterochromatin formation that may underlie certain biological processes.18, 19 Notably, global genomic hypoacetylation at H4K16 is a hallmark of human cancer cells, both cell lines and clinical samples.20
The biological roles of SIRT1, however, are mostly revealed through its deacetylation of a growing number of non-histone substrates that are involved in a wide variety of cellular functions, particularly in metabolic, oxidative/genotoxic and oncogenic stress responses. These substrates can be broadly categorized as: (1) transcriptional factors p53, FOXO1, FOXO3a, NF-κB, c-MYC, N-MYC, E2F1, and HIF-1α/HIF-2α, for regulating cell cycle progression and promoting survival under various conditions; (2) DNA repair machinery elements Ku70, RAD51, NBS1, APE1, XPA/C and WRN, for improving DNA damage repair; (3) Nuclear receptor, circadian clock and related factors LXR, FXR, ERα, AR, PPARγ, PGC1α, CLOCK, and PER2, for regulating metabolism; (4) histone-modifying enzymes SUV39H1, p300, TIP60 and PCAF, for regulating gene expression; (5) cell signaling molecules STAT3, β-catenin and SMAD7, as detailed in previous reviews.21, 22
SIRT1, genetic stability and tumor suppression
Several studies using mouse models provide evidence that SIRT1 may improve genetic stability and suppress tumor formation (Table 1). SIRT1 is a critical gene for mouse early development. Homozygous deletion of SIRT1 (ΔExon5-6 or Δxon5-7) results in peri- and post-natal lethality in C57BL/6 and 129 strains.23, 24 More severe and early embryonic lethality phenotype occurs in another strain with mixed genetic background containing FVB upon SIRT1 deletion (ΔExon5-6).25 In C57BL/6 -129 background, wild type and SIRT1−/− mouse embryonic stem cells (ESCs) exhibit similar levels of chromosomal abnormality, but SIRT1−/− ESCs are more prone to genomic instability under oxidative stress.26 In mixed FVB background, SIRT1−/− early embryos and mouse embryonic fibroblasts display markedly increased spontaneous gross chromosomal abnormalities accompanied with altered global histone modifications.25 The genetic instability in SIRT1−/− embryonic cells is attributed to defective DNA damage repair characterized by reduced γH2AX foci formation and reduced recruitment of DNA damage repair factors to the foci.25, 26 In accord with reduced genetic stability upon SIRT1 loss, SIRT1 heterozygous deletion accelerates tumor formation in p53+/− knockout mice.25
Table 1.
Mouse cancer phenotypes with sirtuin gene knockout or over-expression
Sirtuin | Genotype | Phenotype | Organ sites of tumors |
Role of Sirtuins | Reference |
---|---|---|---|---|---|
SIRT1 | Constitutive deletion of SIRT1 |
SIRT1 knockout inhibited BCR-ABL transformation and CML development |
Blood | cancer promoting | Yuan et al (39) |
| |||||
SIRT1Tg Pten+/− | SIRT1 transgenic mice had increased incidence of thyroid cancer with lung metastases. SIRT1 expression also increased prostate carcinomas in situ. |
Thyroid and prostate |
cancer promoting | Herranz et al (75) | |
| |||||
SIRT1+/− p53+/− | Double heterozygous knockout mice had increased mammary tumor incidence |
Mammary glands | cancer suppressing | Wang RH et al (25) | |
| |||||
Villin-Cre SIRT1ΔSTOP APCmin/+ |
Intestinal SIRT1 expression reduced intestinal tumors |
Intestine | cancer suppressing | Firestein et al (27) | |
| |||||
Mx-Cre SIRT1ΔSTOP p53+/− |
SIRT1 over-expression reduced overall tumor incidence, particularly thymic lymphoma, in p53+/− background |
Thymus | cancer suppressing | Oberdoerffer et al (26) |
|
| |||||
SIRT1Tg | Transgenic SIRT1 mice had reduced incidence of spontaneous carcinomas and sarcomas, but not lymphoma. SIRT1Tg mice had lower incidence of carcinogen-induced liver carcinomas |
Liver, and other epithelial and mesenchymal tissues |
cancer suppressing | Herranz et al (11) | |
| |||||
SIRT2 | Constitutive deletion of SIRT2. |
SIRT2−/− female mice developed mammary tumors, while males predominately developed liver cancers and intestinal tumors |
Liver and intestine in males and mammary glands in females |
cancer suppressing | Kim et al (142) |
| |||||
SIRT3 | Constitutive deletion of SIRT3 |
SIRT3−/− female mice developed mammary tumors with 35% penetrance at about 24 months of age. |
Mammary glands | cancer suppressing | Kim et al (164) |
| |||||
SIRT6 | Constitutive SIRT6 deletion |
Premature aging and death at post- natal week 3 |
- | - | Mostoslavsky et al (192) |
| |||||
Villin-Cre SIRT6fl/fl APC+/− |
SIRT6−/− mice developed larger intestinal tumors |
Intestine | cancer suppressing | Sebastian et al (200) |
No tumors have been reported in constitutive SIRT4, SIRT5 and SIRT7 knockout mice.
Using a conditional SIRT1 over-expression allele that is specifically expressed in the cells lining the intestine, Firestein et al. showed that SIRT1 over-expression reduces intestinal tumor formation in APC+/min mice.27 They demonstrated that SIRT1 deacetylates β-catenin and reduces its nuclear presence and trans-activation potential. Similarly, Oberdoerffer et al showed that SIRT1 conditional over-expression reduces tumor burden in p53+/− mice.26 In a recent report, Herranz et al undertook a three-year study of SIRT1 transgenic mice with SIRT1 over-expression under its own promoter, and showed that increased SIRT1 expression by 3 fold improves healthy mouse aging and reduces spontaneous carcinomas and sarcomas, as well as carcinogen-induced liver cancer incidence.11 Taken together, in vivo mouse models suggest that SIRT1 may improve genetic stability of normal cells and suppress tumor formation.
In addition to genetic stability, SIRT1 may regulate other pathways that contribute to its tumor suppression function. SIRT1 has been shown to inhibit the NF-κB pathway28 that promotes inflammation, survival and cancer metastasis.29 NF-κB is comprised of heterodimers with p65 and p50 subunits. SIRT1 deacetylates the p65/Rel-A subunit of NF-κB and blocks its transactivation of downstream anti-apoptotic target genes, cIAP-2 and BCL-xL.28 Further in line with tumor suppressor function, SIRT1 acts downstream of BRCA1 to negatively regulate the anti-apoptotic gene, Survivin, by deacetylating H3K9 on its promoter and thereby repressing its transcription. Thus, BRCA1 ablation, via reduced SIRT1, results in elevated Survivin levels and enhances tumor growth.30
Dysregulation of SIRT1 gene expression and enzymatic activity in cancer
Although SIRT1 has tumor suppression function in the mouse studies described above, so far there is no reported functional SIRT1 genetic mutation or deletion, or SIRT1 promoter hypermethylation in human cancer. The Sanger’s Catalogue of Somatic Mutations in Cancer (COSMIC) database registers only 14 uncharacterized point mutations among 4357 unique samples as of December 2012, perhaps as background mutations.
In contrast to rare SIRT1 genetic alterations, numerous studies have revealed that human cancer samples display elevated levels of SIRT1 relative to their non-transformed counterparts. These studies span different cancer types including liver,31 breast,32 gastric,33 prostate34, 35 and hematopoietic36-41 origin. In colorectal cancer, Kabra et al observed reduction of SIRT1 expression42, but Nosho et al showed that SIRT1 over-expression correlates with microsatellite instability as well as a CpG Island methylator phenotype.43 Similarly, in mice, over-expression of SIRT1 is reported in leukemia, lymphoma, sarcoma, lung adenocarcinoma and prostate cancer.34, 39, 44, 45
Alteration of SIRT1 gene expression in cancer is mediated by multiple mechanisms affecting transcription, translation and post-translational modifications. At the transcriptional level, tumor suppressor HIC1 directly represses SIRT1 transcription thereby leading to acetylation and activation of another tumor suppressor p53 (ref. 44, and Fig. 2). Loss of HIC1 results in deacetylation of p53 and survival of aged and damaged cells, which may predispose them to cancers.46, 47 p53 itself has been shown to directly repress SIRT1 transcription as well.48 Conversely, SIRT1 is up-regulated by oncogenic transformation in several settings. Yuan et al have recently shown that transformation of hematopoietic stem/progenitor cells by oncogenic tyrosine kinase BCR-ABL activates SIRT1 transcription in part through STAT5 (signal transducer and activator of transcription 5).39 STAT5 is downstream of numerous cytokine and growth factor receptor signaling cascades and is constitutively active in many cancer types.49 STAT5 also acts downstream of BCR-ABL protein in chronic myelogenous leukemia (CML).50, 51 STAT5 directly binds the SIRT1 promoter and enhances SIRT1 expression in CML cells39 (See Fig. 2). SIRT1 levels are increased stepwise from normal hematopoietic cells to chronic phase CML to accelerated and blast crisis CML.39 In the same setting, Yuan et al also showed that SIRT1 can be activated by KRAS transformation. Recently, several groups have demonstrated that MYC (c-MYC and N-MYC) proto-oncogenes directly activates SIRT1 transcription.52-54 This occurs despite incomplete agreement of its effect on MYC protein stability: three groups showing that SIRT1 and MYC form a positive feedback loop in which SIRT1 deacetylates MYC and enhances MYC protein stability; 52, 54, 55 whereas another group showing that SIRT1 destabilizes c-MYC protein.53 In addition, the cell cycle and apoptosis regulator E2F1 induces SIRT1 transcription when cancer cells are under genotoxic stress.56
Fig 2.
Regulation of SIRT1 gene expression and activities in cancer cells
SIRT1 transcription is activated by Myc, E2F1, or BCR-ABL in part through STAT5, but repressed by HIC1 and p53. The sites for transcriptional factor binding are shown. SIRT1 mRNA is stabilized by HuR but degraded by miR34a and miR200a. SIRT1 activity is enhanced by AROS but inhibited by DBC1.
At the message level, SIRT1 expression is increased by stabilizing its mRNA in cancer cells. MicroRNAs (miRs) are small, RNA polymerase II-transcribed genes that generally form clusters and operate by binding to the 3′ untranslated regions (UTR) of genes and thereby negatively regulating mRNA stability and/or translation.57 Several families of miRs have been shown to negatively regulate SIRT1, particularly miR-34a.58 The chromosomal region where miR-34a resides is frequently lost in human cancers, while re-introduction of miR-34a into cancer cells triggers apoptosis.59, 60 Other miR families including miR-200a that target SIRT1 have been characterized as possessing tumor suppressor function.32, 57, 61 Conversely, SIRT1 mRNA is stabilized by RNA binding protein HuR62 that plays a role in promoting tumor cell proliferation and survival.63-65
SIRT1 protein stability is regulated by phosphorylation, sumoylation and ubiquitination. SIRT1 phosphorylation by cycle-dependent kinase Cyclin B/CDK1 controls cell proliferation.66 The dual specificity tyrosine phosphorylation-regulated kinases DYRK1A and DYRK3 phosphorylate SIRT1 and increase SIRT1 enzymatic activity to promote cell survival.67 SIRT1 phosphorylation by c-Jun N-ternimal kinase 2 (JNK2) stabilizes the protein,68 whereas SIRT1 phosphorylation by JNK1 facilitates ubiqitination-mediated degradation.69 Under genotoxic stress, the proapoptotic nuclear desumoylase SENP1 removes SIRT1 sumoylation and reduces its deacetylase activity.70
Finally, SIRT1 enzymatic activity could be regulated during tumorigenesis. Deleted in breast cancer 1 (DBC1) is a tumor suppressor that is lost in a portion of breast cancer patients. DBC1 suppresses SIRT1 activity by direct binding to the SIRT1 catalytic core domain.71, 72 In contrast, active regulator of SIRT1 (AROS) increases SIRT1 activity through direct interaction with N-terminus of SIRT1 protein.73 Furthermore, increasing SIRT1 expression is concomitant with activation of the mammalian NAD+ salvage biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT) in several types of cancer cells to provide sufficient NAD+ for SIRT1 functions, which is important for cancer cell survival and stress response.52, 74
SIRT1 promotes cancer genomic instability and cancer evolution
Several recent studies provide crucial insight into the roles of SIRT1 dysregulation in cancer. Yuan et al demonstrated that SIRT1 homozygous knockout significantly inhibits BCR-ABL transformation of mouse bone marrow stem/progenitor cells and development of CML-like myeloid leukemia in a mouse model in the BALB/c strain.39 In this model, bone marrow cells were harvested from adult wild type and SIRT1−/− mice and transduced by BCR-ABL in vitro followed by transplantation to lethally irradiated syngenic recipients. The effect of SIRT1 knockout on leukemogenesis is thus not influenced by SIRT1 loss on mice, but is a result of cell autonomous impact on leukemia cells. Pharmacological inhibition of SIRT1 also inhibits leukemia development to a similar extent as SIRT1 knockout. This study provides the first genetic evidence for a causal role of dysregulated SIRT1 expression in efficient oncogenic transformation and leukemia progression.
In another study, Herranz et al crossed SIRT1 transgenic (SIRT1tg) mice to PTEN+/− mice, and found that SIRT1 over-expression increased incidence of thyroid carcinomas and their lung metastasis,75 suggesting that increased SIRT1 gene expression has a direct role in promoting tumor progression. These authors found that SIRT1 enhanced Myc stability although they did not directly link deacetylation of Myc to protein stability. Furthermore, Herranz et al showed that PTEN+/− SIRT1tg mice also developed prostate carcinomas in situ, whereas PTEN+/− or SIRT1tg cohort mice did not,75 indicating that SIRT1 over-expression may also have a role in promoting tumor initiation. This study provides additional genetic evidence that SIRT1 activation can facilitate tumorigenesis.
The above studies ostensibly contrast other mouse genetic studies suggesting roles of SIRT1 in tumor suppression as described above. The precise mechanisms for this difference are not clear, but recent studies raise the possibility that SIRT1 might differentially regulate genomic stability in normal versus cancer cells (Fig. 3). In normal cells, loss of SIRT1 causes defective DNA repair leading to genomic instability. Intriguingly, in cancer cells, SIRT1 knockdown also reduces the efficiency of DNA damage repair including both non-homologous end joining (NHEJ) and homologous recombination (HR) repair in CML cells76 and osteosarcoma cells.26 It is shown that SIRT1 is recruited to sites of DNA damage, presumably to remodel local chromatin structure to facilitate repair in cancer cells.77, 78 Therefore, it is likely that SIRT1 may play a role in genome maintenance in both normal and cancer cells. However, this may lead to complex outcomes in cancer cells. On one hand, the maintenance by SIRT1 may ensure cancer cell survival and proliferation (see more in next section) by avoiding deleterious impact of DNA damage on key oncogenes, given that transformation is accompanied with increased production of reactive oxygen species and oxidative DNA damage.79, 80 On the other hand, increased DNA repair by SIRT1 could lead to more mutations in cancer cells and further genomic instability for cancer evolution. This is supported by a recent report by Wang et al showing that SIRT1 promotes de novo acquisition of genetic mutations for drug resistance in CML and prostate cancer cells upon therapeutic (by tyrosine kinase inhibitors) and/or genotoxic (by camptothecin) stress.76 SIRT1 promotion of mutation acquisition is associated with its ability to increase error-prone DNA damage repair in cancer cells, in particular, through deacetylating the key NHEJ repair factor Ku70. Wang et al76 proposed that the unusual effect of SIRT1 in mutation promotion may be attributed to the compromised DNA repair fidelity in cancer cells,81, 82 and thus new genetic mutations may arise as a consequence of misrepair under stress.
Fig. 3.
A model for bifurcated SIRT1 roles in cancer through genome maintenance
SIRT1 promotes genome maintenance in both normal and cancer cells under genotoxic stress and DNA damage. Activation of DNA repair with high fidelity in normal cells improves genome stability and suppresses tumor formation. Activation of DNA repair with low fidelity in cancer cells prevents catastrophic genomic events and renders cancer cell survival, but allows cancer cells to accumulate non-fatal lesions and more mutations to evolve towards high grade malignancy and drug resistance under chemotherapy.
Genomic instability is one of the most critical enabling characteristics of cancer. As cancer progresses towards higher grade malignancy, more mutations are acquired; but, mechanisms for such increasing mutation acquisition are not well understood.15 The new findings by Wang et al may suggest a previously underestimated pathway for cancer genomic instability and evolution, that is to accumulate mutations through enhanced infidelity DNA repair, which has important biological significance for cancer drug resistance.76 SIRT1 appears to be at the center of such an evolution pathway;83 however, more detailed mechanisms still need to be worked out in the future.
SIRT1 promotes cancer hallmark capability
Cancer evolves not only with accumulation of genetic alterations, but also with profound epigenetic changes. Cancer cells display global genomic DNA hypomethylation with concurrent hypermethylation at tumor suppressor gene loci. Additionally, cancer cells display gross aberrant histone modification patterns relative to normal cells.84 In addition to SIRT1 directly deacetylating histone substrates to affect the epigenetic state, SIRT1 can deacetylate DNA methyltransferase 1 (DNMT1) and can either enhance or hinder its methyltransferase activity,85 thus indirectly affecting global or local DNA methylation patterns. SIRT1 is a component of the polycomb repressor complex (PRC) that is involved in silencing genes during normal development. In cancer cells, PRC is also involved in silencing tumor suppressor genes.86, 87 The catalytic subunit of the PRC II complex is EZH2 that is responsible for trimethylation of H3K27 88 and itself a noted proto-oncogene frequently mutated in human cancers.89 SIRT1 directly complexes with EZH2 and other components of the PRC complex and is an integral part of the PRC’s silencing functions.90 Kuzmichev et al identified a SIRT1-containing PRC complex, termed PRC4, that is specifically found in transformed cells and ESCs.45 Inhibition of SIRT1 has been shown to reactivate silenced tumor suppressor genes.91 In addition, SIRT1 interacts and deacetylates the SUV39H1 methyltransferase, promoting histone H3 methylation and fostering heterochromatin formation92 and repressing rRNA transcription to protect cells from energy deprivation-dependent apoptosis.93 The dysregulated epigenome by SIRT1 in cancer cells may act in concert with genetic alterations to facilitate cancer evolution and reach the biological endpoint hallmarks.15 This section will discuss the cancer hallmarks that are affected by SIRT1.
Cancer hallmark 1: resisting cell death. SIRT1 regulates multiple cell death pathways. SIRT1 deacetylates p53 at lysine 382, reducing its transcriptional activity and leading to a blockade of p53-dependent apoptosis in response to DNA damage signals.94, 95 Similar patterns are observed for p73, which is part of the p53 family.96 Leukemia stem cells are typically refractory to chemotherapy. Recently, Li et al. have demonstrated that inhibiting SIRT1 in CD34+ CML stem/progenitor cells results in enhanced p53 acetylation, transcriptional activity and apoptosis of these cells, and sensitizes them to the BCR-ABL inhibitor, imatinib, both in vitro and in vivo. This effect is dependent on p53 as cells with p53 knockdown fail to respond to SIRT1 inhibition.40 This study reveals a novel drug resistance mechanism mediated by SIRT1 in leukemia stem cells.
The intrinsic apoptotic pathway is tightly orchestrated by the BCL-2 family that contains pro- and anti-apoptotic members, of which Bax is the prototypical pro-apoptotic gene.97 Cancer cells can resist apoptosis by sequestering Bax from mitochondria. This is accomplished through the non-canonical action of Ku70.98 SIRT1 regulates Bax sequestration through deacetylation of Ku70, thereby increasing Ku70 interaction with Bax and blocking Bax translocation to mitochondria.99 By modulating Ku70, SIRT1 inhibition induces apoptosis in leukemia cells lacking p53 in vitro and suppresses growth of tumor xenograft in vivo.39
The transcriptional regulator BCL6 is also subjected to deacetylation by SIRT1.100 BCL6 is expressed in the germinal center within lymph nodes and represses genes that are involved in cell cycle regulation, apoptosis and differentiation.101 Translocations involving BCL6 are a frequent event in B-cell lymphomas.102, 103 Deacetylation by SIRT1 promotes BCL6 transcriptional repression activity and resists cell apoptosis.100 Heltweg et al. demonstrate that a chemical inhibitor of SIRT1, Cambinol, has anti-lymphoma properties in vitro and in vivo in part by preventing the deacetylation and activation of BCL6.104
As described above, SIRT1 can promote cancer cell death resistance by facilitating acquisition of genetic mutations.76 In addition, SIRT1 promotes chemotherapy resistance by enhancing efflux of drugs. Chu et al report that SIRT1 is elevated in drug resistant cell lines as well as in patient samples.105 SIRT1 increases the expression of multi-drug resistance 1 (MDR1) in cancer cells, while inhibition of SIRT1 sensitizes these cancer cells to anti-cancer drugs. Another group reported that a novel SIRT1 inhibitor, Amurensin G, reduces expression of MDR1 and sensitizes otherwise resistant cells to cytotoxic drugs.106
Cancer hallmark 2: sustaining proliferation signaling. As discussed above, SIRT1 is activated by MYC and forms a positive feedback loop to stabilize MYC protein in most studies. Stabilized MYC further enables cell proliferative signaling and stimulates cell growth. This likely explains why Burkitt’s lymphoma, that is initiated by c-MYC transformation, is most sensitive to the SIRT1 inhibitor Cambinol used as a single agent.104 SIRT1 is also shown to regulate WNT signaling,107 and WNT activation is associated with transcriptional activation of c-MYC in high grade malignancy of colorectal cancer in the serrated route.108
Cancer hallmark 3: evading growth suppressors. As described above, SIRT1 deacetylates and inactivates p53, a negative cell cycle regulator, to bypass growth arrest. Another key tumor suppressor family that is deacetylated by SIRT1 is the Forkhead transcription factors (FOXO).109-112 FOXO transcription factors are involved in cell cycle control113 as well as anti-oxidant and DNA damage repair pathways.114 Motta et al showed that SIRT1 deacetylation of FOXO3a suppresses FOXO3-mediated cell apoptosis induction, in parallel to p53 inhibition.110 Wang et al showed that deacetylation of FOXO3 by SIRT1 or SIRT2 results in its ubiquitination and subsequent degradation,115 thereby facilitating cell cycle progression and contributing to the promotion of cancer.
Cancer hallmark 4: inducing angiogenesis. It is known that SIRT1 controls endothelial angiogenic functions through deacetylating FOXO1 and Notch1 intracellular domain (NICD) during vascular growth.116, 117 SIRT1 enhances tumor angiogenesis through negatively modulating Delta-like ligand 4 (DLL4)/Notch signaling in Lewis lung carcinoma xenograft-derived vascular endothelial cells.118 SIRT1 also activates endothelial nitric oxide synthase by deacetylation to enhance nitric oxide production and improve vascular function.119
Cancer hallmark 5: Activating invasion and metastasis. Epithelial-to-mesenchymal transition (EMT) is an essential process to promote cancer invasion and metastasis. It has been shown that SIRT1 is activated during EMT-like transformation of mammary epithelial cells, in part due to epigenetic silencing of miR-200a, which negatively regulates SIRT1.32 SIRT1 is also a positive regulator of EMT and metastasis of prostate cancer.120 Overexpression of SIRT1 induces EMT through transcription factor ZEB1 in prostate cancer cells; SIRT1 knockdown restores cell-cell adhesion and reverses EMT of prostate cancer cells in vitro and in vivo.120
Cancer hallmark 6: deregulating cellular energetics and tumor microenvironment. The hypoxiainducible transcription factors HIF-1 and HIF-2 are activated in cancer cells due to chronically low oxygen tension in the tumor bulk. HIF-1 activates numerous genes that promote angiogenesis, survival and glucose uptake, all necessary for tumor growth. HIF-1 is emerging as a major player in metastasis, chemo and radiotherapy resistance.121 HIF-1α is the regulatory subunit of HIF-1 and is subjected to post-translational modification.122, 123 Lim et al. showed that SIRT1 can deacetylate HIF-1α and repress its biological function in vitro and in tumor xenografts.124 However, such effect of SIRT1 on HIF-1α has been recently disputed by Laemmle et al showing that SIRT1 stabilizes HIF-1α under hypoxia and SIRT1 inhibition impairs hypoxic response of hepatocellular carcinoma cells.125 Laemmle’s study is in line with a previous report demonstrating that SIRT1 helps cells survive against hypoxic environment by activating HIF-2α.126
Summary of SIRT1 and Cancer
All the data so far suggest that SIRT1 has both pro and anti cancer roles. We propose that SIRT1 may act as a genome caretaker in normal cells and therefore suppress tumorigenesis. However, upon oncogenic events, tumor cells co-opt SIRT1-regulated cellular pathways to promote unabated proliferation, progression, resisting death signals, and genetic/epigenetic evolution. Such dual roles in tumorigenesis are not unprecedented. For examples, TERT can both hinder and promote tumor formation;16 TGFβ can be antiproliferative but is redirected towards promoting EMT and high-grade malignancy at the later stages of tumorigenesis;127 aberrant DNA hypermethylation by DNMT1 promotes tumorigenesis by silencing tumor suppressor genes but DNMT1 deletion or expression of a hypomorphic allele in mice results in tumorigenesis.128, 129 As such, the precise role of SIRT1 in tumorigenesis may be dependent on cellular and molecular contexts.
SIRT2
Biochemical Overview
SIRT2 shares certain biochemical parallels with SIRT1. SIRT2 has thus far been characterized primarily as an NAD+ dependent protein deacetylase. Although being mostly cytoplasmic, SIRT2 can translocate to the nucleus where it deacetylates H4K16 during mitosis.130, 131 SIRT2 has also been shown to deacetylate H3K56.132 Much fewer non-histone substrates have thus far been identified for SIRT2. Alpha-tubulin is the first known SIRT2 substrate,133 but the exact biological role of tubulin acetylation/deacetylation remains elusive. Sharing substrates with SIRT1, SIRT2 also deacetylates FOXO1,134, 135 FOXO3,115, 136 and p53137-139 for regulating autophagy, apoptosis and differentiation. Most recently, SIRT2 is shown to regulate programmed necrosis by targeting receptor-interacting proteins.140 Mitotic regulation is another biological function frequently ascribed to SIRT2 as detailed in a previous review.141 Kim et al. described that SIRT2 regulates mitosis by deacetylating components of the anaphase-promoting complex/cyclosome (APC/C) ubiquitin ligase machinery to enhance its activity, directing degradation of Aurora kinases as cells exit mitosis.142 In the dietary obesity setting, the intra-adipose tissue hypoxia and activation of HIF-1α results in transcriptional repression of SIRT2, leading to increased acetylation of PGC-1a and affecting β-oxidation and mitochondrial gene expression.143
SIRT2 and Cancer
Analogous to the bifurcated results with SIRT1 in cancer, SIRT2 has both roles in tumor suppression and promotion. SIRT2 is reported to be a tumor suppressor in gliomas 144, 145 and melanomas146 with chromosomal loss at the SIRT2 locus and point mutations within the catalytic domain that abrogates its enzymatic activity. SIRT2 expression is reduced in certain cancers,142, 145, 147 and gene silencing by histone deacetylation is associated with SIRT2 downregulation in glioma cells.148 However, forced SIRT2 expression only moderately reduces proliferation of glioma cells.149 The direct support of SIRT2’s tumor suppressor role is provided by Kim et al. showing that SIRT2 knockout mice develop tumors in various organs due to abnormal chromosomal segregation and aneuploidy caused by increased expression of mitotic regulators including Aurora kinases upon SIRT2 knockout.142
On the other hand, it is observed that SIRT2 may promote oncogenic phenotypes. SIRT2 is increased in acute myeloid leukemia (AML) cells compared to normal bone marrow cells, and SIRT2 inhibition causes apoptosis of AML cells in vitro.150 Hou et al. showed that SIRT2 expression positively correlates with Cortactin in high-grade prostate cancer samples and predicts poor prognosis.151 Knockdown of SIRT2 induces p53 accumulation and promotes apoptosis of cancer cells.138, 139 Recently, Liu et al showed that SIRT2 is activated by N-MYC in neuroblastoma cells and by c-MYC in pancreatic cancer cells. Activated SIRT2 stabilizes NMYC and c-MYC protein and promotes cell proliferation through downregulating ubiquitin-protein ligase NEDD4.152 Liu et al also found that SIRT2 increases Aurora A expression in these cells, in contrast to the finding by Kim et al.142 In this regard, it is worthy to note that Aurora A has bifurcated roles in cancer with either gene over-expression or knockout promoting tumorigenesis.153, 154 More studies are needed to further delineate the precise roles of SIRT2 in cancer.
SIRT3
Biochemical Overview
SIRT3 possesses NAD+ dependent deacetylase as well as ADP ribosyltransferase activity. SIRT3 is the major mitochondrial deacetylase with a broad range of substrates.155 Although principally localized to mitochondria, SIRT3 can be detected in the nucleus as well.156 There are two forms of SIRT3, and processing of the N-terminus results in a smaller protein that localizes to mitochondria.157, 158 Within the nucleus, SIRT3 deacetylates H4K16 and H3K9 to repress transcription.156 In mitochondria, SIRT3 regulates metabolism, energy homeostasis, thermogenesis and mitochondrial biogenesis. For a more thorough review on SIRT3 and metabolic regulation, we refer the readers to other reviews.159, 160 SIRT3 increases fatty acid β-oxidation by deacetylating and therefore enhancing the activity of Long Chain Acyl CoA Dehydrogenase.161 The catabolism of fatty acids by β-oxidation yields acetyl CoA, which gets further metabolized by the Krebs cycle. SIRT3 regulates several components of the Krebs cycle and electron transport chain to promote ATP production.160, 162 This is punctuated by the phenotype seen in SIRT3 knockout mice that show reduced cellular ATP levels as well as increased reactive oxygen species (ROS).162 Uncontrolled ROS in the cell results in DNA and protein damage, aging and cancer.163
SIRT3 and Cancer
SIRT3 acts like a tumor suppressor as evidenced by increased mammary tumor formation in SIRT3 knockout mice.164 One major tumor suppression mechanism of SIRT3 is through modulation of ROS. As noted above, SIRT3−/− cells show increased ROS due to faulty electron transport.162, 164, 165 Another means by which SIRT3 regulates ROS is through activation of anti-oxidant enzymes, such as superoxide dismutase that is a major mitochondrial detoxifying enzyme.166, 167 Further, Someya et al revealed that SIRT3 lowers ROS by deacetylation and activation of mitochondrial isocitrate dehydrogenase 2, which in turn increases NADPH levels and the abundance of active glutathione, a major cellular anti-oxidant.168 Deacetylation and activation of FOXO3a by SIRT3 also promotes its activation of anti-oxidant enzymes.169 Yet another mechanism whereby SIRT3 reduces ROS and therefore tumorigenesis is in its capacity to destabilize HIF-1α.165, 170 Because of SIRT3’s effect in regulating oxidative phosphorylation and HIF-1, SIRT3−/− cells may be further prone to cancer by shifting its metabolism toward aerobic glycolysis, a phenomenon termed the Warburg effect that is thematic of most cancer cells.171, 172 The studies with SIRT3 knockout mice lend credence to the notion that SIRT3 acts to protect against tumorigenesis. However, it is unclear why SIRT3 knockout only increases mouse mammary tumors, given that these pathways are not mammary gland specific.
In human cancers, Kim et al. showed that SIRT3 protein and mRNA are reduced in breast cancer.164 Consistently, Bell et al. showed that knockdown of SIRT3 in human cancer cells increases tumors size and reduces latency when injected into mice.165 Conversely, forced expression of SIRT3 blocks proliferation and reduces tumor xenografts. Finley et al. found that about 20% of all human cancer samples and 40% of breast and ovarian cancer samples contain deletions of SIRT3.170
Recently, a novel tumor suppressor function of SIRT3 was uncovered in its ability to deacetylate the proto-oncogene, Skp2.173 Skp2 is over-expressed in a wide range of cancers and its expression levels foretell a poor clinical prognosis. Skp2 functions biochemically as an E3 ubiquitin ligase and is responsible for targeting numerous tumor suppressors such as p21 and p27 for proteasome-mediated degradation.174 Deacetylation of Skp2 by SIRT3 leads to its nuclear import where Skp2 is excluded from targeting E-cadherin. In contrast, acetylated Skp2 gets exported to the cytoplasm where it ubiquitinates E-cadherin for proteasome-mediated degradation.173 Reduced E-cadherin is observed in many cancers and is a feature of EMT and cancer metastases.175 Together, these studies indicate that SIRT3 suppresses tumorigenesis.
Yet, as with SIRT1 and SIRT2, there are opposing studies that propose a tumor promoting role for SIRT3. Alhazzazi et al showed that SIRT3 levels are elevated in oral squamous carcinoma cell lines and patient samples, and that knockdown of SIRT3 in OSCC lines reduces cell viability and proliferation as well as tumors in xenografts.176 Ectopic SIRT3 expression reverses p53-induced cell cycle arrest and senescence, which would provide a mechanism for a tumor-promoting role of SIRT3.177 Like SIRT1, SIRT3 can deacetylate Ku70 and thereby facilitate its interaction with Bax to mitigate Bax-mediated apoptosis.178 These studies, albeit few and contradictory, provide some evidence that SIRT3 may have a cell protective role under stress and may give cancer cells a growth advantage.
SIRT4
SIRT4 is a mitochondrial ADP-ribosyltransferase without recognized deacetylase activity. Its primary function thus far uncovered is in regulation of metabolic function. In vitro, SIRT4 can ADP-ribosylate histones.179 SIRT4 ADP-ribosylates glutamate dehydrogenase (GDH) and inhibits its catalytic activity. GDH catalyzes the conversion of glutamate to α-ketoglutarate (α-KG).179, 180 Yang et al. reported that SIRT3 and SIRT4 are required for cell viability in response to genotoxic stress along with NAMPT to maintain NAD+ levels within mitochondria.181
To date, there are no systematic studies evaluating the role of SIRT4 in cancer. Though, Bradbury et al. revealed that SIRT4 levels are consistently down in AML samples.41 Speculatively, since SIRT4 regulates α-KG production from glutamate, we wonder what role SIRT4 may play on α-KG-dependent enzymes that have been shown to be involved in tumorigenesis, such as the TET enzymes and jmjC histone demethylases.182, 183 Metabolic dysfunction leading to abnormal epigenetic regulation and ultimately tumorigenesis has a precedent as is seen with isocitrate dehydrogenase mutations in several types of cancers.184, 185
SIRT5
Mitochondrial SIRT5 is perhaps the most unusual of sirtuins as it possess NAD+ dependent deacetylase as well as deacylase (demalonylase and desuccinylase) activities.4 The best studied substrate of SIRT5 is carbamoyl phosphate synthetase 1 (CPS1) for the rate-limiting step in urea synthesis. Several groups have demonstrated that SIRT5 can deacetylate, demalonylate and desuccinylate CPS1.4, 186, 187 Deacetylation of CPS1 activates its enzymatic activity that promotes the production of urea and clearance of excessive ammonia from the cell. The biological significance of demolonylation and desuccinylation of CPS1 by SIRT5 remains unknown.188 To date, there are no studies evaluating the role of SIRT5 in tumorigenesis.
SIRT6
Biochemical Overview
SIRT6 is a chromatin bound NAD+ dependent deacetylase and ADP-ribosyltransferase.189 Its major histone substrates are H3K9 and H3K56.190, 191 Michisita et al. showed that SIRT6 associates with telomeres and deacetylates H3K9 to maintain proper telomeric chromatin,190 and disruption of telomere functions likely accounts for the premature aging phenotype observed in SIRT6−/− mice.192 SIRT6 plays an integral role in DNA repair pathways including BER,192 HR,193, 194 and NHEJ.195, 196 SIRT6 can ADP-ribosylate PARP1 leading to its activation and promotion of double strand break repair.196 Intriguingly, over-expression of SIRT6, but not SIRT1, increases NHEJ and HR repair efficiency in non-malignant cells.196 Kawahara et al. demonstrated that SIRT6 is recruited with NF-κB to deacetylate H3K9 and silence its target genes.197 SIRT6 is also a co-repressor of HIF1 and represses expression of the genes involved in energy metabolism by deacetylating H3K9.198
SIRT6 and Cancer
Forced expression of SIRT6 induces apoptosis of cancer cells but not in non-transformed cells.199 SIRT6-mediated apoptosis of cancer cells requires its ADP-ribosyltransferase, but not deacetylase, activity, as well as the intact ATM and p53 pathways.199 Mice with constitutive SIRT6 knockout display genetic instability and die of a premature aging syndrome approximately 25 days post-natally.192 Using a conditional gene knockout strategy, Sebastian et al. very recently demonstrated a role of SIRT6 in tumor suppression.200 These authors revealed that loss of SIRT6 is sufficient to transform immortalized mouse embryonic fibroblasts. Conditional knockout of SIRT6 in the intestine of APCMin/+ mice results in increased tumor incidence, in part by de-repression of Myc activity and activation of aerobic glycolysis. They further showed that SIRT6 is frequently deleted and its expression is significantly reduced in human cancer samples. Together with SIRT6’s roles in genome maintenance, the data so far suggest that SIRT6 may act as a tumor suppressor.
SIRT7
Biochemical Overview
SIRT7 is primarily a deacetylase and is localized to the nucleolus as well as the nucleus.3 Within nucleoli, SIRT7 regulates ribosomal DNA gene expression in part by activating RNA polymerase I.201 SIRT7 deacetylates H3K18, specifically, to repress transcription.202 SIRT7 is also shown to deacetylate p53 in vitro and in vivo, and SIRT7 ablation increases p53-mediated apoptosis.203
SIRT7 and Cancer
Several groups showed that SIRT7 is elevated in human cancers of breast,204 thyroid205 and liver206 origin. Ford et al. demonstrated that knockdown of SIRT7 inhibits cell growth and induces apoptosis.201 Barber et al. showed that knockdown of SIRT7 in cancer cell lines reduces cell growth both in vitro and in vivo, and demonstrated a novel oncogenic mechanism of SIRT7 by deacetylating H3K18.202 Interestingly, many different cancers display global hypoacetylation of H3K18, which is associated with a poor prognosis in prostate cancers.207, 208 Viral oncogenes can stimulate hypoacetylation of H3K18.209, 210 Consistently, Barber et al. showed that knockdown of SIRT7 abolishes adenoviral E1A-mediated proliferation and transformation of fibroblasts.202 These studies point to a growth advantage that SIRT7 renders cancer cells. Further in vivo studies should be undertaken to evaluate roles of SIRT7 in cancer in the future.
Concluding remarks
Studies of sirtuins are rapidly growing in the field of cancer and other diseases. Sirtuins are generally involved in stress response, DNA damage repair and metabolism. SIRT1, SIRT2 and SIRT3 appear to have both roles in tumor inhibition and promotion. Despite the controversy, it appears that SIRT1 has a consistent role in mediating cancer cell survival, in particular for drug resistance, and that SIRT6 has more pronounced roles in tumor suppression. Currently, both sirtuin activators and inhibitors have been developed or under development, and they may be suited for distinct therapeutic purposes.211 For cancer treatment, inhibitors like tenovin-6212 and cambinol104 that targets both SIRT1 and SIRT2 have shown anti-tumor effects in vivo. However, sirtuin modulators are in general not specific and potent enough. Given the complex roles of each sirtuin, future effort is needed to develop more selective sirtuin modulators for human use to treat cancer or other diseases. We expect to see continued rapid growth in sirtuin research in coming years that will help us better understand functions of this family of proteins for the good of human health.
Acknowledgements
The authors would like to acknowledge the research support from the National Cancer Institute of the National Institutes of Health under award number R01 CA143421, and the State of California Tobacco Related Disease Research Program (TRDRP) award 20XT-0121 to W.Y.C. The contents are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health.
Footnotes
Conflict of Interest Statement: The authors declare no conflict of interest with respect to the authorship and/or publication of this article.
References
- 1.Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. doi: 10.1038/35001622. [DOI] [PubMed] [Google Scholar]
- 2.Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun. 2000;273(2):793–8. doi: 10.1006/bbrc.2000.3000. [DOI] [PubMed] [Google Scholar]
- 3.Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med. 2012 doi: 10.1016/j.freeradbiomed.2012.10.525. [DOI] [PubMed] [Google Scholar]
- 4.Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334(6057):806–9. doi: 10.1126/science.1207861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404(1):1–13. doi: 10.1042/BJ20070140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tissenbaum HA, Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature. 2001;410(6825):227–30. doi: 10.1038/35065638. [DOI] [PubMed] [Google Scholar]
- 7.Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999;13(19):2570–80. doi: 10.1101/gad.13.19.2570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rogina B, Helfand SL. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A. 2004;101(45):15998–6003. doi: 10.1073/pnas.0404184101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–6. doi: 10.1038/nature01960. [DOI] [PubMed] [Google Scholar]
- 10.Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004;430(7000):686–9. doi: 10.1038/nature02789. [DOI] [PubMed] [Google Scholar]
- 11.Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3. doi: 10.1038/ncomms1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, Piper MD, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 2011;477(7365):482–5. doi: 10.1038/nature10296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010;10(12):819–23. doi: 10.1038/nrc2962. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218–21. doi: 10.1038/nature10815. [DOI] [PubMed] [Google Scholar]
- 15.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
- 16.Weinberg RA. The biology of cancer. Garland Science; New York: 2007. p. xix.p. 796.p. 48. [Google Scholar]
- 17.Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell. 2004;16(1):93–105. doi: 10.1016/j.molcel.2004.08.031. [DOI] [PubMed] [Google Scholar]
- 18.Vaquero A. The conserved role of sirtuins in chromatin regulation. Int J Dev Biol. 2009;53(2-3):303–22. doi: 10.1387/ijdb.082675av. [DOI] [PubMed] [Google Scholar]
- 19.Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000;14(9):1021–6. [PubMed] [Google Scholar]
- 20.Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400. doi: 10.1038/ng1531. [DOI] [PubMed] [Google Scholar]
- 21.Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nature Reviews Molecular Cell Biology. 2012;13(4):225–238. doi: 10.1038/nrm3293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–504. doi: 10.1038/sj.onc.1210616. [DOI] [PubMed] [Google Scholar]
- 23.McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol. 2003;23(1):38–54. doi: 10.1128/MCB.23.1.38-54.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003;100(19):10794–9. doi: 10.1073/pnas.1934713100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14(4):312–23. doi: 10.1016/j.ccr.2008.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008;135(5):907–18. doi: 10.1016/j.cell.2008.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008;3(4):e2020. doi: 10.1371/journal.pone.0002020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J. 2004;23(12):2369–80. doi: 10.1038/sj.emboj.7600244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6(5):327–34. doi: 10.1038/cmi.2009.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008;32(1):11–20. doi: 10.1016/j.molcel.2008.09.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, et al. SIRT1 and c-Myc Promote Liver Tumor Cell Survival and Predict Poor Survival of Human Hepatocellular Carcinomas. PLoS One. 2012;7(9):e45119. doi: 10.1371/journal.pone.0045119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011;286(29):25992–6002. doi: 10.1074/jbc.M111.229401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 2009;15(13):4453–9. doi: 10.1158/1078-0432.CCR-08-3329. [DOI] [PubMed] [Google Scholar]
- 34.Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612–8. doi: 10.1158/0008-5472.CAN-07-0085. [DOI] [PubMed] [Google Scholar]
- 35.Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 2009;284(6):3823–32. doi: 10.1074/jbc.M807869200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M, Shirasawa S, et al. High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer. 2012;131(9):2044–55. doi: 10.1002/ijc.27481. [DOI] [PubMed] [Google Scholar]
- 37.Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology. 2011;81(5-6):325–9. doi: 10.1159/000334577. [DOI] [PubMed] [Google Scholar]
- 38.Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32(10):1523–31. doi: 10.1097/PAS.0b013e31816b6478. [DOI] [PubMed] [Google Scholar]
- 39.Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012;119(8):1904–14. doi: 10.1182/blood-2011-06-361691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012;21(2):266–81. doi: 10.1016/j.ccr.2011.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751–9. doi: 10.1038/sj.leu.2403910. [DOI] [PubMed] [Google Scholar]
- 42.Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem. 2009;284(27):18210–7. doi: 10.1074/jbc.M109.000034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2009;22(7):922–32. doi: 10.1038/modpathol.2009.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123(3):437–48. doi: 10.1016/j.cell.2005.08.011. [DOI] [PubMed] [Google Scholar]
- 45.Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, Kirmizis A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A. 2005;102(6):1859–64. doi: 10.1073/pnas.0409875102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003;33(2):197–202. doi: 10.1038/ng1077. [DOI] [PubMed] [Google Scholar]
- 47.Chen WY, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell. 2004;6(4):387–98. doi: 10.1016/j.ccr.2004.08.030. [DOI] [PubMed] [Google Scholar]
- 48.Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004;306(5704):2105–8. doi: 10.1126/science.1101731. [DOI] [PubMed] [Google Scholar]
- 49.Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 2008;22(6):711–21. doi: 10.1101/gad.1643908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13(2):247–54. [PubMed] [Google Scholar]
- 51.Ilaria RL, Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704–10. doi: 10.1074/jbc.271.49.31704. [DOI] [PubMed] [Google Scholar]
- 52.Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A. 2012;109(4):E187–96. doi: 10.1073/pnas.1105304109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Yuan J, Minter-Dykhouse K, Lou Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J Cell Biol. 2009;185(2):203–11. doi: 10.1083/jcb.200809167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet. 2011;7(6):e1002135. doi: 10.1371/journal.pgen.1002135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, et al. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol. 2011;43(11):1573–81. doi: 10.1016/j.biocel.2011.07.006. [DOI] [PubMed] [Google Scholar]
- 56.Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006;8(9):1025–31. doi: 10.1038/ncb1468. [DOI] [PubMed] [Google Scholar]
- 57.Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97. doi: 10.1016/s0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
- 58.Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105(36):13421–6. doi: 10.1073/pnas.0801613105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26(34):5017–22. doi: 10.1038/sj.onc.1210293. [DOI] [PubMed] [Google Scholar]
- 60.Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52. doi: 10.1016/j.molcel.2007.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I, et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 2011;6(5):e20600. doi: 10.1371/journal.pone.0020600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Abdelmohsen K, Pullmann R, Jr., Lal A, Kim HH, Galban S, Yang X, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell. 2007;25(4):543–57. doi: 10.1016/j.molcel.2007.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Danilin S, Sourbier C, Thomas L, Lindner V, Rothhut S, Dormoy V, et al. Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis. 2010;31(6):1018–26. doi: 10.1093/carcin/bgq052. [DOI] [PubMed] [Google Scholar]
- 64.Nowotarski SL, Shantz LM. Cytoplasmic accumulation of the RNA-binding protein HuR stabilizes the ornithine decarboxylase transcript in a murine nonmelanoma skin cancer model. J Biol Chem. 2010;285(41):31885–94. doi: 10.1074/jbc.M110.148767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilen ST, Laakso M, et al. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol. 2011;224(4):529–39. doi: 10.1002/path.2889. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, Stukenberg PT, et al. Phosphorylation regulates SIRT1 function. PLoS One. 2008;3(12):e4020. doi: 10.1371/journal.pone.0004020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Guo X, Williams JG, Schug TT, Li X. DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem. 2010;285(17):13223–32. doi: 10.1074/jbc.M110.102574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Ford J, Ahmed S, Allison S, Jiang M, Milner J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle. 2008;7(19):3091–7. doi: 10.4161/cc.7.19.6799. [DOI] [PubMed] [Google Scholar]
- 69.Gao Z, Zhang J, Kheterpal I, Kennedy N, Davis RJ, Ye J. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem. 2011;286(25):22227–34. doi: 10.1074/jbc.M111.228874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 2007;9(11):1253–62. doi: 10.1038/ncb1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008;451(7178):587–90. doi: 10.1038/nature06515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature. 2008;451(7178):583–6. doi: 10.1038/nature06500. [DOI] [PubMed] [Google Scholar]
- 73.Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell. 2007;28(2):277–90. doi: 10.1016/j.molcel.2007.08.030. [DOI] [PubMed] [Google Scholar]
- 74.Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 2011;30(8):907–21. doi: 10.1038/onc.2010.468. [DOI] [PubMed] [Google Scholar]
- 75.Herranz D, Maraver A, Canamero M, Gomez-Lopez G, Inglada-Perez L, Robledo M, et al. SIRT1 promotes thyroid carcinogenesis driven by PTEN deficiency. Oncogene. 2012 doi: 10.1038/onc.2012.407. DOI:10.1038/onc.2012.407. [DOI] [PubMed] [Google Scholar]
- 76.Wang Z, Yuan H, Roth M, Stark JM, Bhatia R, Chen WY. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. 2013;32:589–598. doi: 10.1038/onc.2012.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.O’Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 2008;4(8):e1000155. doi: 10.1371/journal.pgen.1000155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.O’Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 2011;20(5):606–19. doi: 10.1016/j.ccr.2011.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107(19):8788–93. doi: 10.1073/pnas.1003428107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319–27. doi: 10.1182/blood-2005-07-2815. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12):3746–53. doi: 10.1182/blood-2004-05-1941. [DOI] [PubMed] [Google Scholar]
- 82.Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006;5(2):243–50. doi: 10.1016/j.dnarep.2005.10.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Chen WY. Accelerating cancer evolution: a dark side of SIRT1 in genome maintenance. Oncotarget. 2012;3(4):363–4. doi: 10.18632/oncotarget.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92. doi: 10.1016/j.cell.2007.01.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Peng L, Yuan Z, Ling H, Fukasawa K, Robertson K, Olashaw N, et al. SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol. 2011;31(23):4720–34. doi: 10.1128/MCB.06147-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39(2):157–8. doi: 10.1038/ng1941. [DOI] [PubMed] [Google Scholar]
- 87.Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007;39(2):237–42. doi: 10.1038/ng1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298(5595):1039–43. doi: 10.1126/science.1076997. [DOI] [PubMed] [Google Scholar]
- 89.Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17(9):2613–8. doi: 10.1158/1078-0432.CCR-10-2156. [DOI] [PubMed] [Google Scholar]
- 90.Furuyama T, Banerjee R, Breen TR, Harte PJ. SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex. Curr Biol. 2004;14(20):1812–21. doi: 10.1016/j.cub.2004.09.060. [DOI] [PubMed] [Google Scholar]
- 91.Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006;2(3):e40. doi: 10.1371/journal.pgen.0020040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature. 2007;450(7168):440–4. doi: 10.1038/nature06268. [DOI] [PubMed] [Google Scholar]
- 93.Murayama A, Ohmori K, Fujimura A, Minami H, Yasuzawa-Tanaka K, Kuroda T, et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell. 2008;133(4):627–39. doi: 10.1016/j.cell.2008.03.030. [DOI] [PubMed] [Google Scholar]
- 94.Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149–59. doi: 10.1016/s0092-8674(01)00527-x. [DOI] [PubMed] [Google Scholar]
- 95.Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107(2):137–48. doi: 10.1016/s0092-8674(01)00524-4. [DOI] [PubMed] [Google Scholar]
- 96.Dai JM, Wang ZY, Sun DC, Lin RX, Wang SQ. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity. J Cell Physiol. 2007;210(1):161–6. doi: 10.1002/jcp.20831. [DOI] [PubMed] [Google Scholar]
- 97.Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122(Pt 4):437–41. doi: 10.1242/jcs.031682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol. 2003;5(4):320–9. doi: 10.1038/ncb950. [DOI] [PubMed] [Google Scholar]
- 99.Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305(5682):390–2. doi: 10.1126/science.1099196. [DOI] [PubMed] [Google Scholar]
- 100.Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–13. doi: 10.1038/ng1018. [DOI] [PubMed] [Google Scholar]
- 101.Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13(2):199–212. doi: 10.1016/s1074-7613(00)00020-0. [DOI] [PubMed] [Google Scholar]
- 102.Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262(5134):747–50. doi: 10.1126/science.8235596. [DOI] [PubMed] [Google Scholar]
- 103.Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet. 1993;5(1):66–70. doi: 10.1038/ng0993-66. [DOI] [PubMed] [Google Scholar]
- 104.Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66(8):4368–77. doi: 10.1158/0008-5472.CAN-05-3617. [DOI] [PubMed] [Google Scholar]
- 105.Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005;65(22):10183–7. doi: 10.1158/0008-5472.CAN-05-2002. [DOI] [PubMed] [Google Scholar]
- 106.Oh WK, Cho KB, Hien TT, Kim TH, Kim HS, Dao TT, et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol. 2010;78(5):855–64. doi: 10.1124/mol.110.065961. [DOI] [PubMed] [Google Scholar]
- 107.Holloway KR, Calhoun TN, Saxena M, Metoyer CF, Kandler EF, Rivera CA, et al. SIRT1 regulates Dishevelled proteins and promotes transient and constitutive Wnt signaling. Proc Natl Acad Sci U S A. 2010;107(20):9216–21. doi: 10.1073/pnas.0911325107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Kriegl L, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget. 2012;3(10):1182–93. doi: 10.18632/oncotarget.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–5. doi: 10.1126/science.1094637. [DOI] [PubMed] [Google Scholar]
- 110.Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116(4):551–63. doi: 10.1016/s0092-8674(04)00126-6. [DOI] [PubMed] [Google Scholar]
- 111.van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1) J Biol Chem. 2004;279(28):28873–9. doi: 10.1074/jbc.M401138200. [DOI] [PubMed] [Google Scholar]
- 112.Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci U S A. 2004;101(27):10042–7. doi: 10.1073/pnas.0400593101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Ho KK, Myatt SS, Lam EW. Many forks in the path: cycling with FoxO. Oncogene. 2008;27(16):2300–11. doi: 10.1038/onc.2008.23. [DOI] [PubMed] [Google Scholar]
- 114.Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008;18(9):421–9. doi: 10.1016/j.tcb.2008.07.004. [DOI] [PubMed] [Google Scholar]
- 115.Wang F, Chan CH, Chen K, Guan X, Lin HK, Tong Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene. 2012;31(12):1546–57. doi: 10.1038/onc.2011.347. [DOI] [PubMed] [Google Scholar]
- 116.Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature. 2011;473(7346):234–8. doi: 10.1038/nature09917. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21(20):2644–58. doi: 10.1101/gad.435107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Xie M, Liu M, He CS. SIRT1 regulates endothelial Notch signaling in lung cancer. PLoS One. 2012;7(9):e45331. doi: 10.1371/journal.pone.0045331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104(37):14855–60. doi: 10.1073/pnas.0704329104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31(43):4619–29. doi: 10.1038/onc.2011.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol. 2011;4(1):62–77. doi: 10.2174/1874467211104010062. [DOI] [PubMed] [Google Scholar]
- 122.Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–8. doi: 10.1126/science.1059817. [DOI] [PubMed] [Google Scholar]
- 123.Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72. doi: 10.1126/science.1059796. [DOI] [PubMed] [Google Scholar]
- 124.Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell. 2010;38(6):864–78. doi: 10.1016/j.molcel.2010.05.023. [DOI] [PubMed] [Google Scholar]
- 125.Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1alpha protein under hypoxic conditions. PLoS One. 2012;7(3):e33433. doi: 10.1371/journal.pone.0033433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009;324(5932):1289–93. doi: 10.1126/science.1169956. [DOI] [PubMed] [Google Scholar]
- 127.Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415–24. doi: 10.1038/nrc2853. [DOI] [PubMed] [Google Scholar]
- 128.Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature. 1998;395(6697):89–93. doi: 10.1038/25779. [DOI] [PubMed] [Google Scholar]
- 129.Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300(5618):455. doi: 10.1126/science.1083557. [DOI] [PubMed] [Google Scholar]
- 130.Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 2006;20(10):1256–61. doi: 10.1101/gad.1412706. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.North BJ, Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2007;2(8):e784. doi: 10.1371/journal.pone.0000784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature. 2009;459(7243):113–7. doi: 10.1038/nature07861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11(2):437–44. doi: 10.1016/s1097-2765(03)00038-8. [DOI] [PubMed] [Google Scholar]
- 134.Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007;6(2):105–14. doi: 10.1016/j.cmet.2007.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S, et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 2010;12(7):665–75. doi: 10.1038/ncb2069. [DOI] [PubMed] [Google Scholar]
- 136.Wang F, Nguyen M, Qin FX, Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell. 2007;6(4):505–14. doi: 10.1111/j.1474-9726.2007.00304.x. [DOI] [PubMed] [Google Scholar]
- 137.Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun. 2008;368(3):690–5. doi: 10.1016/j.bbrc.2008.01.114. [DOI] [PubMed] [Google Scholar]
- 138.Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 2011;16(1):34–45. doi: 10.1111/j.1365-2443.2010.01460.x. [DOI] [PubMed] [Google Scholar]
- 139.Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010;9(4):844–55. doi: 10.1158/1535-7163.MCT-09-0971. [DOI] [PubMed] [Google Scholar]
- 140.Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, et al. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature. 2012;492(7428):199–204. doi: 10.1038/nature11700. [DOI] [PubMed] [Google Scholar]
- 141.Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle. 2007;6(9):1011–8. doi: 10.4161/cc.6.9.4219. [DOI] [PubMed] [Google Scholar]
- 142.Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487–99. doi: 10.1016/j.ccr.2011.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Krishnan J, Danzer C, Simka T, Ukropec J, Walter KM, Kumpf S, et al. Dietary obesity-associated Hif1alpha activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. Genes Dev. 2012;26(3):259–70. doi: 10.1101/gad.180406.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 144.Nahhas F, Dryden SC, Abrams J, Tainsky MA. Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem. 2007;303(1-2):221–30. doi: 10.1007/s11010-007-9478-6. [DOI] [PubMed] [Google Scholar]
- 145.Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003;309(3):558–66. doi: 10.1016/j.bbrc.2003.08.029. [DOI] [PubMed] [Google Scholar]
- 146.Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013–8. doi: 10.1073/pnas.0500090102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010;139(6):1995–2004. e15. doi: 10.1053/j.gastro.2010.05.080. [DOI] [PubMed] [Google Scholar]
- 148.Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, et al. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2007;26(7):945–57. doi: 10.1038/sj.onc.1209857. [DOI] [PubMed] [Google Scholar]
- 149.North BJ, Verdin E. Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J Biol Chem. 2007;282(27):19546–55. doi: 10.1074/jbc.M702990200. [DOI] [PubMed] [Google Scholar]
- 150.Dan L, Klimenkova O, Klimiankou M, Klusman JH, van den Heuvel-Eibrink MM, Reinhardt D, et al. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica. 2012;97(4):551–9. doi: 10.3324/haematol.2011.055236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Hou H, Chen W, Zhao L, Zuo Q, Zhang G, Zhang X, et al. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ. J Clin Pathol. 2012;65(12):1088–96. doi: 10.1136/jclinpath-2012-200940. [DOI] [PubMed] [Google Scholar]
- 152.Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2012 doi: 10.1038/cdd.2012.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Lu LY, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem. 2008;283(46):31785–90. doi: 10.1074/jbc.M805880200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene. 2006;25(54):7148–58. doi: 10.1038/sj.onc.1209707. [DOI] [PubMed] [Google Scholar]
- 155.Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807–14. doi: 10.1128/MCB.01636-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev. 2007;21(8):920–8. doi: 10.1101/gad.1527307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Cooper HM, Huang JY, Verdin E, Spelbrink JN. A new splice variant of the mouse SIRT3 gene encodes the mitochondrial precursor protein. PLoS One. 2009;4(3):e4986. doi: 10.1371/journal.pone.0004986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 2002;158(4):647–57. doi: 10.1083/jcb.200205057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Huang JY, Hirschey MD, Shimazu T, Ho L, Verdin E. Mitochondrial sirtuins. Biochim Biophys Acta. 2010;1804(8):1645–51. doi: 10.1016/j.bbapap.2009.12.021. [DOI] [PubMed] [Google Scholar]
- 160.Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010;35(12):669–75. doi: 10.1016/j.tibs.2010.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–5. doi: 10.1038/nature08778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 162.Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A. 2008;105(38):14447–52. doi: 10.1073/pnas.0803790105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 163.Tudek B, Winczura A, Janik J, Siomek A, Foksinski M, Olinski R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am J Transl Res. 2010;2(3):254–84. [PMC free article] [PubMed] [Google Scholar]
- 164.Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41–52. doi: 10.1016/j.ccr.2009.11.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 165.Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011;30(26):2986–96. doi: 10.1038/onc.2011.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166.Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010;40(6):893–904. doi: 10.1016/j.molcel.2010.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 167.Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12(6):662–7. doi: 10.1016/j.cmet.2010.11.015. [DOI] [PubMed] [Google Scholar]
- 168.Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010;143(5):802–12. doi: 10.1016/j.cell.2010.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 169.Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758–71. doi: 10.1172/JCI39162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 170.Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19(3):416–28. doi: 10.1016/j.ccr.2011.02.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 171.Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14. doi: 10.1126/science.123.3191.309. [DOI] [PubMed] [Google Scholar]
- 172.Haigis MC, Deng CX, Finley LW, Kim HS, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2010;72(10):2468–72. doi: 10.1158/0008-5472.CAN-11-3633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 173.Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, et al. Acetylation-dependent regulation of Skp2 function. Cell. 2012;150(1):179–93. doi: 10.1016/j.cell.2012.05.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 174.Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6):438–49. doi: 10.1038/nrc2396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 175.Tiwari N, Gheldof A, Tatari M, Christofori G. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22(3):194–207. doi: 10.1016/j.semcancer.2012.02.013. [DOI] [PubMed] [Google Scholar]
- 176.Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D’Silva NJ, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117(8):1670–8. doi: 10.1002/cncr.25676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 177.Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ. p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One. 2010;5(5):e10486. doi: 10.1371/journal.pone.0010486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 178.Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008;28(20):6384–401. doi: 10.1128/MCB.00426-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 179.Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell. 2006;126(5):941–54. doi: 10.1016/j.cell.2006.06.057. [DOI] [PubMed] [Google Scholar]
- 180.Herrero-Yraola A, Bakhit SM, Franke P, Weise C, Schweiger M, Jorcke D, et al. Regulation of glutamate dehydrogenase by reversible ADP-ribosylation in mitochondria. Embo J. 2001;20(10):2404–12. doi: 10.1093/emboj/20.10.2404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 181.Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130(6):1095–107. doi: 10.1016/j.cell.2007.07.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 182.Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326–38. doi: 10.1101/gad.191056.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 183.Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi: 10.1016/j.ccr.2010.12.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 184.Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–67. doi: 10.1016/j.ccr.2010.11.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 185.Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–8. doi: 10.1038/nature10860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 186.Ogura M, Nakamura Y, Tanaka D, Zhuang X, Fujita Y, Obara A, et al. Overexpression of SIRT5 confirms its involvement in deacetylation and activation of carbamoyl phosphate synthetase 1. Biochem Biophys Res Commun. 2010;393(1):73–8. doi: 10.1016/j.bbrc.2010.01.081. [DOI] [PubMed] [Google Scholar]
- 187.Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009;137(3):560–70. doi: 10.1016/j.cell.2009.02.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 188.Newman JC, He W, Verdin E. Mitochondrial Protein Acylation and Intermediary Metabolism: Regulation by Sirtuins and Implications for Metabolic Disease. J Biol Chem. 2012 doi: 10.1074/jbc.R112.404863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 189.Liszt G, Ford E, Kurtev M, Guarente L. Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J Biol Chem. 2005;280(22):21313–20. doi: 10.1074/jbc.M413296200. [DOI] [PubMed] [Google Scholar]
- 190.Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;452(7186):492–6. doi: 10.1038/nature06736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 191.Michishita E, McCord RA, Boxer LD, Barber MF, Hong T, Gozani O, et al. Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle. 2009;8(16):2664–6. doi: 10.4161/cc.8.16.9367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 192.Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315–29. doi: 10.1016/j.cell.2005.11.044. [DOI] [PubMed] [Google Scholar]
- 193.Kaidi A, Weinert BT, Choudhary C, Jackson SP. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science. 2010;329(5997):1348–53. doi: 10.1126/science.1192049. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 194.Mao Z, Tian X, Van Meter M, Ke Z, Gorbunova V, Seluanov A. Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence. Proc Natl Acad Sci U S A. 2012;109(29):11800–5. doi: 10.1073/pnas.1200583109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 195.McCord RA, Michishita E, Hong T, Berber E, Boxer LD, Kusumoto R, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY) 2009;1(1):109–21. doi: 10.18632/aging.100011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 196.Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011;332(6036):1443–6. doi: 10.1126/science.1202723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 197.Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 2009;136(1):62–74. doi: 10.1016/j.cell.2008.10.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 198.Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010;140(2):280–93. doi: 10.1016/j.cell.2009.12.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 199.Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle. 2011;10(18):3153–8. doi: 10.4161/cc.10.18.17435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 200.Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, et al. The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism. Cell. 2012;151(6):1185–99. doi: 10.1016/j.cell.2012.10.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 201.Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006;20(9):1075–80. doi: 10.1101/gad.1399706. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 202.Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487(7405):114–8. doi: 10.1038/nature11043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 203.Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008;102(6):703–10. doi: 10.1161/CIRCRESAHA.107.164558. [DOI] [PubMed] [Google Scholar]
- 204.Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer. 2006;95(8):1056–61. doi: 10.1038/sj.bjc.6603384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 205.de Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer. 2002;86(6):917–23. doi: 10.1038/sj.bjc.6600156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 206.Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, et al. SIRT7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors mir-125a-5p and mir-125b. Hepatology. 2012 doi: 10.1002/hep.26101. [DOI] [PubMed] [Google Scholar]
- 207.Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262–6. doi: 10.1038/nature03672. [DOI] [PubMed] [Google Scholar]
- 208.Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174(5):1619–28. doi: 10.2353/ajpath.2009.080874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 209.Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. Epigenetic reprogramming by adenovirus e1a. Science. 2008;321(5892):1086–8. doi: 10.1126/science.1155546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 210.Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science. 2008;321(5892):1084–5. doi: 10.1126/science.1155544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 211.Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008;7(10):841–53. doi: 10.1038/nrd2665. [DOI] [PubMed] [Google Scholar]
- 212.Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13(5):454–63. doi: 10.1016/j.ccr.2008.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]